Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
The Ministry of Health, Labor and Welfare (MHLW) on June 12 announced the final report of its expert panel discussing comprehensive policies for the rapid and stable supply of pharmaceuticals following fine-tuning based on opinions raised by panelists on June…
To read the full story
Related Article
- Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
- Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
June 7, 2023
- Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
- Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
- Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
REGULATORY
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
- MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…